Tiffany Inglis, Sera Prognostics CMO, sells $972 in shares

Tiffany Eul Davis Inglis, Chief Medical Officer at Sera Prognostics, Inc., sold 486 shares of the company's Class A Common Stock on September 10, 2026, according to wire material. The sale, totaling $972, was made to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and followed a mandatory policy set by Sera Prognostics.

The weighted average price for the shares sold was $2.00, with each share traded between $2.00 and $2.03. Ms. Inglis currently holds 91,589 shares of the company. Sera Prognostics, with a market capitalization of $79 million, has more cash than debt on its balance sheet, indicating the stock is undervalued according to InvestingPro analysis.

The company recently reported a wider-than-expected loss and revenue lower than analyst projections in its second quarter of 2026, but noted improvements in testing volumes, payer interest, and clinical evidence.